LUNAR IIIb study comparing rosuvastatin and atorvastatin in subjects with acute coronary syndromes
Study identifier:4522US/0001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 12-week randomized, open-label 3-arm, parallel group, multicenter Phase IIIb study comparing efficacy and safety of rosuvastatin 20mg and 40mg with that of atorvastatin 80 mg in subjects with acute coronary syndromes
Medical condition
Acute Coronary Syndromes
Phase
Phase 3
Healthy volunteers
No
Study drug
rosuvastatin calcium, atorvastatin
Sex
All
Actual Enrollment
825
Study type
Interventional
Age
18 Years - 70 Years
Date
Study Start Date: 01 Dec 2003
Primary Completion Date: 01 Aug 2007
Study Completion Date: 01 Aug 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Crestor Medical Science Director
AstraZeneca
